{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:35:18Z","timestamp":1793799318077,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"U.S. Department of Defense Kidney Cancer Research Program (KCRP) Idea Development Award","award":["HT9425-23-1-0516"],"award-info":[{"award-number":["HT9425-23-1-0516"]}]},{"name":"U.S. Department of Defense Kidney Cancer Research Program (KCRP) Idea Development Award","award":["HT9425-23-1-0516"],"award-info":[{"award-number":["HT9425-23-1-0516"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02382-y","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:45:13Z","timestamp":1750229113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biologically targeted dual adaptive and innate nano-Immunotherapy for clear cell renal cell carcinoma treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Kin Man","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2382_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Cancer J Clin. 2024;74:12\u201349.","journal-title":"Cancer J Clin"},{"key":"2382_CR2","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.2012.475","volume":"307","author":"HJ Tan","year":"2012","unstructured":"Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA. 2012;307:1629\u201335.","journal-title":"JAMA"},{"key":"2382_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000499299","volume":"13","author":"M Quinlan","year":"2019","unstructured":"Quinlan M, Wei G, Davis N, Poyet C, Perera M, Bolton D, Lawrentschuk N. Renal cell carcinoma Follow-Up - Is it time to abandon ultrasound? Curr Urol. 2019;13:19\u201324.","journal-title":"Curr Urol"},{"key":"2382_CR4","doi-asserted-by":"publisher","first-page":"e389650","DOI":"10.1200\/EDBK_389650","volume":"43","author":"CC Fahey","year":"2023","unstructured":"Fahey CC, Shevach JW, Flippot R, Albiges L, Haas NB, Beckermann KE. Triplet strategies in metastatic clear cell renal cell carcinoma: A worthy option in the First-Line setting? Am Soc Clin Oncol Educ Book. 2023;43:e389650.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2382_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","volume":"17","author":"P Makhov","year":"2018","unstructured":"Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies. Mol Cancer Ther. 2018;17:1355\u201364.","journal-title":"Mol Cancer Ther"},{"key":"2382_CR6","doi-asserted-by":"crossref","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Reviews Disease Primers 2017, 3.","DOI":"10.1038\/nrdp.2017.9"},{"key":"2382_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ctrv.2018.07.009","volume":"70","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127\u201337.","journal-title":"Cancer Treat Rev"},{"key":"2382_CR8","doi-asserted-by":"crossref","unstructured":"Choi SH, Chen Y-W, Panian J, Yuen K, McKay RR. Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma. Oncologist 2024.","DOI":"10.1093\/oncolo\/oyae276"},{"key":"2382_CR9","doi-asserted-by":"crossref","unstructured":"Takacova M, Barathova M, Zatovicova M, Golias T, Kajanova I, Jelenska L, Sedlakova O, Svastova E, Kopacek J, Pastorekova S. Carbonic anhydrase IX\u2014Mouse versus human. Int J Mol Sci 2019, 21.","DOI":"10.3390\/ijms21010246"},{"key":"2382_CR10","first-page":"7","volume":"1","author":"D Zahavi","year":"2018","unstructured":"Zahavi D, AlDeghaither D, O\u2019Connell A, Weiner LM. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther. 2018;1:7\u201312.","journal-title":"Antib Ther"},{"key":"2382_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0022-5347(05)00040-6","volume":"175","author":"I Bleumer","year":"2006","unstructured":"Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, V\u00f6ller MCW, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PFA. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose Interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol. 2006;175:57\u201362.","journal-title":"J Urol"},{"key":"2382_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/sj.bjc.6601617","volume":"90","author":"I Bleumer","year":"2004","unstructured":"Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer. 2004;90:985\u201390.","journal-title":"Br J Cancer"},{"key":"2382_CR13","doi-asserted-by":"crossref","unstructured":"Chamie K, Donin NM, Kl\u00f6pfer P, Bevan P, Fall B, Wilhelm O, St\u00f6rkel S, Said J, Gambla M, Hawkins RE et al. Adjuvant weekly Girentuximab following nephrectomy for High-Risk renal cell carcinoma. JAMA Oncol 2017, 3.","DOI":"10.1001\/jamaoncol.2016.4419"},{"key":"2382_CR14","doi-asserted-by":"publisher","first-page":"LBA602","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA602","volume":"41","author":"BM Shuch","year":"2023","unstructured":"Shuch BM, Pantuck AJ, Bernhard J-C, Morris MA, Master VA, Scott AM, Van Praet C, Bailly C, Aksoy T, Merkx R, et al. Results from phase 3 study of 89Zr-DFO-girentuximab for PET\/CT imaging of clear cell renal cell carcinoma (ZIRCON). J Clin Oncol. 2023;41:LBA602\u2013602.","journal-title":"J Clin Oncol"},{"key":"2382_CR15","doi-asserted-by":"crossref","unstructured":"Siddiqi T. CARs vs bispecifics: the race is on! Blood. 2024;144:592\u20133.","DOI":"10.1182\/blood.2024025130"},{"key":"2382_CR16","doi-asserted-by":"crossref","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J 2024, 14.","DOI":"10.1038\/s41408-024-00997-w"},{"key":"2382_CR17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","volume":"11","author":"DS Vinay","year":"2012","unstructured":"Vinay DS, Kwon BS. Immunotherapy of Cancer with 4-1BB. Mol Cancer Ther. 2012;11:1062\u201370.","journal-title":"Mol Cancer Ther"},{"key":"2382_CR18","doi-asserted-by":"publisher","first-page":"2167189","DOI":"10.1080\/19420862.2023.2167189","volume":"15","author":"C Claus","year":"2023","unstructured":"Claus C, Ferrara-Koller C, Klein C. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs. 2023;15:2167189.","journal-title":"MAbs"},{"key":"2382_CR19","doi-asserted-by":"crossref","unstructured":"Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open 2019, 4.","DOI":"10.1136\/esmoopen-2019-000629"},{"key":"2382_CR20","doi-asserted-by":"crossref","unstructured":"Thomas LJ, He L-Z, Marsh H, Keler T. Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. OncoImmunology 2014, 3.","DOI":"10.4161\/onci.27255"},{"key":"2382_CR21","doi-asserted-by":"publisher","first-page":"eaba8564","DOI":"10.1126\/sciadv.aba8564","volume":"6","author":"KM Au","year":"2020","unstructured":"Au KM, Park SI, Wang AZ. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci Adv. 2020;6:eaba8564.","journal-title":"Sci Adv"},{"key":"2382_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/eji.201646837","volume":"47","author":"D Cibrian","year":"2017","unstructured":"Cibrian D, Sanchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017;47:946\u201353.","journal-title":"Eur J Immunol"},{"key":"2382_CR23","doi-asserted-by":"publisher","first-page":"e2836","DOI":"10.1038\/cddis.2017.67","volume":"8","author":"P Bhat","year":"2017","unstructured":"Bhat P, Leggatt G, Waterhouse N, Frazer IH. Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 2017;8:e2836\u20132836.","journal-title":"Cell Death Dis"},{"key":"2382_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1128\/CDLI.8.6.1131-1135.2001","volume":"8","author":"S Neri","year":"2001","unstructured":"Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol. 2001;8:1131\u20135.","journal-title":"Clin Diagn Lab Immunol"},{"key":"2382_CR25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/IAI.68.2.752-759.2000","volume":"68","author":"D Haller","year":"2000","unstructured":"Haller D, Blum S, Bode C, Hammes WP, Schiffrin EJ. Activation of human peripheral blood mononuclear cells by nonpathogenic bacteria in vitro: evidence of NK cells as primary targets. Infect Immun. 2000;68:752\u20139.","journal-title":"Infect Immun"},{"key":"2382_CR26","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1002569107","volume":"107","author":"C Krieg","year":"2010","unstructured":"Krieg C, L\u00e9tourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci. 2010;107:11906\u201311.","journal-title":"Proc Natl Acad Sci"},{"key":"2382_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/ni.2180","volume":"13","author":"NS Butler","year":"2011","unstructured":"Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, Tygrett LT, Waldschmidt TJ, Crompton PD, Harty JT. Therapeutic Blockade of PD-L1 and LAG-3 rapidly clears established blood-stage plasmodium infection. Nat Immunol. 2011;13:188\u201395.","journal-title":"Nat Immunol"},{"key":"2382_CR28","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.4049\/jimmunol.0802830","volume":"182","author":"DD Kish","year":"2009","unstructured":"Kish DD, Li X, Fairchild RL. CD8 T cells producing IL-17 and IFN-\u03b3 initiate the innate immune response required for responses to antigen skin challenge. J Immunol. 2009;182:5949\u201359.","journal-title":"J Immunol"},{"key":"2382_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/TP.0b013e3181e228bd","volume":"90","author":"H Shariff","year":"2010","unstructured":"Shariff H, Tanriver Y, Brown KL, Meader L, Greenlaw R, Mamode N, Jurcevic S. Intermittent Antibody-Based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients. Transplantation. 2010;90:270\u20138.","journal-title":"Transplantation"},{"key":"2382_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/291334a0","volume":"291","author":"M Kasai","year":"1981","unstructured":"Kasai M, Yoneda T, Habu S, Maruyama Y, Okumura K, Tokunaga T. In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature. 1981;291:334\u20135.","journal-title":"Nature"},{"key":"2382_CR31","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1039\/C8RA08972H","volume":"9","author":"S Rezvantalab","year":"2019","unstructured":"Rezvantalab S, Keshavarz Moraveji M. Microfluidic assisted synthesis of PLGA drug delivery systems. RSC Adv. 2019;9:2055\u201372.","journal-title":"RSC Adv"},{"key":"2382_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40591-015-0044-4","volume":"3","author":"L Ban","year":"2015","unstructured":"Ban L, Kuhtreiber W, Butterworth J, Okubo Y, Vanamee ES, Faustman DL. Strategic internal covalent cross-linking of TNF produces a stable TNF trimer with improved TNFR2 signaling. Mol Cell Ther. 2015;3:7.","journal-title":"Mol Cell Ther"},{"key":"2382_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/physrev.00045.2017","volume":"99","author":"C Dostert","year":"2019","unstructured":"Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev. 2019;99:115\u201360.","journal-title":"Physiol Rev"},{"key":"2382_CR34","doi-asserted-by":"crossref","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, Cheng Q, Luo P, Zhang Y, Han X. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Therapy 2023, 8.","DOI":"10.1038\/s41392-023-01451-2"},{"key":"2382_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2567.2007.02555.x","volume":"120","author":"D Aw","year":"2007","unstructured":"Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435\u201346.","journal-title":"Immunology"},{"key":"2382_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0022-1759(03)00010-3","volume":"275","author":"A Trickett","year":"2003","unstructured":"Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3\/CD28 beads. J Immunol Methods. 2003;275:251\u20135.","journal-title":"J Immunol Methods"},{"key":"2382_CR37","doi-asserted-by":"crossref","unstructured":"Sckisel GD, Mirsoian A, Minnar CM, Crittenden M, Curti B, Chen JQ, Blazar BR, Borowsky AD, Monjazeb AM, Murphy WJ. Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy. J Immunother Cancer 2017, 5.","DOI":"10.1186\/s40425-017-0235-4"},{"key":"2382_CR38","doi-asserted-by":"crossref","unstructured":"de la Harpe KM, Kondiah PPD, Choonara YE, Marimuthu T, du Toit LC, Pillay V. The hemocompatibility of nanoparticles: A review of Cell-Nanoparticle interactions and hemostasis. Cells 2019, 8.","DOI":"10.3390\/cells8101209"},{"key":"2382_CR39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","volume":"10","author":"HH Gustafson","year":"2015","unstructured":"Gustafson HH, Holt-Casper D, Grainger DW, Ghandehari H. Nanoparticle uptake: the phagocyte problem. Nano Today. 2015;10:487\u2013510.","journal-title":"Nano Today"},{"key":"2382_CR40","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.1158\/1078-0432.CCR-21-2372","volume":"28","author":"C Yao","year":"2022","unstructured":"Yao C, Zhang T, Wu T, Brugarolas J. Facts and hopes for immunotherapy in renal cell carcinoma. Clin Cancer Res. 2022;28:5013\u201320.","journal-title":"Clin Cancer Res"},{"key":"2382_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/oncolo\/oyac263","volume":"28","author":"AM Mahmoud","year":"2023","unstructured":"Mahmoud AM, Nabavizadeh R, Rodrigues Pessoa R, Garg I, Orme J, Costello BA, Cheville J, Lucien F. Antibody-Based therapeutics for the treatment of renal cell carcinoma: challenges and opportunities. Oncologist. 2023;28:297\u2013308.","journal-title":"Oncologist"},{"key":"2382_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/KCA-220001","volume":"6","author":"Y Lyou","year":"2022","unstructured":"Lyou Y, Dorff TB. Chimeric antigen receptor (CAR) T-cell treatment in renal cell carcinoma: current clinical trials and future directions. Kidney Cancer. 2022;6:159\u201368.","journal-title":"Kidney Cancer"},{"key":"2382_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13636","volume":"169","author":"Y Yao","year":"2023","unstructured":"Yao Y, Hu Y, Wang F. Trispecific antibodies for cancer immunotherapy. Immunology. 2023;169:389\u201399.","journal-title":"Immunology"},{"key":"2382_CR44","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.7150\/thno.81494","volume":"13","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, Compte M, \u00c1lvarez-Vallina L, Sanz L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics. 2023;13:1028\u201341.","journal-title":"Theranostics"},{"key":"2382_CR45","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.2022016243","volume":"140","author":"L Zhao","year":"2022","unstructured":"Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, Wen F, Zhang J-s, Wang F, Liu Z-l, Cao YJ. A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. 2022;140:1790\u2013802.","journal-title":"Blood"},{"key":"2382_CR46","doi-asserted-by":"crossref","unstructured":"Ye Q-N, Zhu L, Liang J, Zhao D-K, Tian T-Y, Fan Y-N, Ye S-Y, Liu H, Huang X-Y, Cao Z-T et al. Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity. Nat Commun 2024, 15.","DOI":"10.1038\/s41467-024-50474-y"},{"key":"2382_CR47","doi-asserted-by":"crossref","unstructured":"O\u2019Connell RP, Liaw K, Wellhausen N, Chuckran CA, Bhojnagarwala PS, Bordoloi D, Park D, Shupin N, Kulp D, June CH, Weiner D. Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma. J Immunother Cancer 2024, 12.","DOI":"10.1136\/jitc-2023-008733"},{"key":"2382_CR48","doi-asserted-by":"crossref","unstructured":"Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming challenges for CD3-Bispecific antibody therapy in solid tumors. Cancers (Basel) 2021, 13.","DOI":"10.3390\/cancers13020287"},{"key":"2382_CR49","first-page":"135","volume":"11","author":"PH Viale","year":"2020","unstructured":"Viale PH. The American Cancer society\u2019s facts & figures: 2020 edition. J Adv Pract Oncol. 2020;11:135\u20136.","journal-title":"J Adv Pract Oncol"},{"key":"2382_CR50","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-17-1847","volume":"24","author":"T Bartkowiak","year":"2018","unstructured":"Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, Ai M, Reilley MJ, Sebastian MM, Hong DS, Curran MA. Activation of 4-1BB on liver myeloid cells triggers hepatitis via an Interleukin-27-Dependent pathway. Clin Cancer Res. 2018;24:1138\u201351.","journal-title":"Clin Cancer Res"},{"key":"2382_CR51","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1111\/febs.13754","volume":"283","author":"T H\u00fcnig","year":"2016","unstructured":"H\u00fcnig T. The rise and fall of the CD28 superagonist TGN1412 and its return as table 08: a personal account. FEBS J. 2016;283:3325\u201334.","journal-title":"FEBS J"},{"key":"2382_CR52","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.3892\/ijo.2014.2658","volume":"45","author":"M Zatovicova","year":"2014","unstructured":"Zatovicova M, Jelenska L, Hulikova A, Ditte P, Ditte Z, Csaderova L, Svastova E, Schmalix W, Boettger V, Bevan P, et al. Monoclonal antibody G250 targeting CA IX: binding specificity, internalization and therapeutic effects in a non-renal cancer model. Int J Oncol. 2014;45:2455\u201367.","journal-title":"Int J Oncol"},{"key":"2382_CR53","doi-asserted-by":"crossref","unstructured":"Chang D-K, Moniz RJ, Xu Z, Sun J, Signoretti S, Zhu Q, Marasco WA. Human anti-CAIX antibodies mediate immune cell Inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol Cancer 2015, 14.","DOI":"10.1186\/s12943-015-0384-3"},{"key":"2382_CR54","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2967\/jnumed.123.267175","volume":"65","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Tran B, Feldman DR, Pokorska-Bocci A, Pichereau S, Wessen J, Haskali MB, Sparks RB, Vlasyuk O, Galetic I. First-in-Human safety, imaging, and dosimetry of a carbonic anhydrase IX\u2013Targeting peptide, [68Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma. J Nucl Med. 2024;65:740\u20133.","journal-title":"J Nucl Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02382-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02382-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02382-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:05:22Z","timestamp":1751382322000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02382-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02382-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author requested to update the Author contributions texts to \u201cInvestigation: K.M.A. and S.L.; analysis: K.M.A.; design and supervision: K.M.A., A.Z.W. and T.Z.; funding acquisition: A.Z.W. and T.Z.; manuscript preparation: K.M.A. (original draft); A.Z.W. and T.Z. (review). All authors reviewed and approved the final manuscript\u201d.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the University of Texas Southwestern Medical Center Institutional Animal Care (protocol 2023-103631) following the Guideline for the Care and Use of Laboratory Animals (NIH publication no. 86\u2009\u2212\u200923, revised 1985).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have consented to submit this article for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}